Workers at the NIH sent a letter protesting the Trump administration’s cuts to the agency's budget, staff, and research.

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

Study results highlight the need to improve adverse event cost quantification in oncology cost-effectiveness analyses, researchers say.

Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.

Nivolumab plus ipilimumab did not improve OS vs chemotherapy in patients with previously untreated, unresectable/metastatic urothelial carcinoma.

Younger cancer survivors were more likely than their older peers to start alcohol use disorder treatment within 1 year of diagnosis. Less than 15% of cancer survivors diagnosed with alcohol use ...

Pediatric patients with diffuse midline gliomas may have better outcomes if they have a more diverse gut microbiome.

The FDA has granted de novo authorization to CLAIRITY BREAST, a platform that uses AI to help predict a woman's risk of breast cancer.

Though some cancer patients lack sufficient enzymes to metabolize capecitabine or 5-FU, many patients are not warned about the risks associated with these treatments.

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.

The Trump administration is changing the emergency abortion guidance currently in place at the nation's hospitals.

The US Food and Drug Administration (FDA) has expanded the approved use of Nubeqa (darolutamide) for patients with metastatic castration-sensitive prostate cancer (mCSPC). The drug is now approved for ...